Discussion
inflammation, dyslipidemia
INFLAMMATION, EVENTS, EVENTS, DYSLIPIDEMIA
We investigated the effects of pitavastatin on atherosclerotic-associated inflammatory biomarkers in PLHIV who had dyslipidemia and receiving ritonavir-boosted atazanavir. Although pitavastatin significantly lowered serum total cholesterol and LDL-cholesterol [The INTREPID study compared the effects of pitavastatin (4 mg daily) versus pravastatin (40 mg daily) on markers of immune activation and arterial inflammation in PLHIV and revealed greater reduction in soluble CD14, oxidized LDL, and lipoprotein-associated phospholipase 2, which are markers of immune activation and arterial inflammation, in the pitavastatin arm at week 52 [Our results showed significantly different changes in the proportions of T cell subsets of HLA-DRThe strength of our study included the double-blind, crossover study design which could minimize the biases. However, we accepted the limitations of the small sample size, and the short duration of the washout period. Some independent markers of cardiovascular disease-related mortality, i.e., sCD14, D-dimer, and fibrinogen, were not studied. Further, the short duration of follow-up did not allow for the detection of clinical outcome of cardiovascular events. A large prospective trial, for example, Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) [